We are an experienced group of scientists and business leaders, with a long history of bringing new medicines to the people who need them
Damon Smith: Ph.D
Damon has over 30 years of pharmaceutical experience, 20 in senior management and board roles in both the UK and North America. Starting life with Therapeutic Antibodies UK (where he led the company’s cytokine/sepsis program) Damon came to Canada in 2000 spending 11 years as SVP R&D at Labopharm during which time he and his team developed and commercialized a number of pain/CNS medicines. In 2012 Damon founded Altus Formulation Inc. where he has been CEO for the last 8 years. Damon has participated in three successful IPO and has been responsible for numerous licensing agreements with development and commercialization partners. Damon is a co-founder of TALLC.
Sylvain Guenette: CPA
Chief Financial Officer
Sylvain served as Vice-President, Finance for the American Iron & Metal Company Inc. from 2012 to 2020 prior to which he was employed as CFO of Labopharm a publicly traded Montreal pharmaceutical company. Prior to joining Labopharm, Sylvain was Corporate Controller Les Systèmes Proxima Ltée, an international software development company and held various finance and operations positions with the Quebecor group.
Sonia Gervais: MSc.
Chief Operating Officer
Sonia has over 20 years of large, medium and small pharmaceutical company experience and has played a leading roles in the registration of a number of FDA approved products. In 2013, her role as a co-founder of Altus Formulation Inc. placed her at the heart of the pharmaceutical operations, designing and implementing business operation strategies and setting goals for performance and growth. Sonia took on the multifaceted scientific, technical, logistics and regulatory challenges of a start-up to exploit the potential of the company’s complex proprietary technologies while optimizing the operating capabilities within strict budget controls.
Monique Champagne Ph.D
Head Clinical Development
Monique Champagne is a pharmacist with over 30 years of experience in clinical research, drug development and regulatory affairs, acquired in the pharmaceutical, biotechnology and contract industries. A creative leader and manager, she has extensive practical experience and expertise in the first phases of product development, in clinical development in various therapeutic areas, clinical operations management, regulatory affairs and strategic planning, integration and improvement of operational processes, as well as in managing international projects and professional relations with business partners.
Prior executive positions held by Ms. Champagne include President & Chief Executive Officer of Ilkos Therapeutic Inc. and Vice-President, Clinical Research and Regulatory Affairs at Telesta Therapeutics.
Marc Lemieux: Ph.D
Vice President Product Development
Marc is a multidisciplinary research scientist with Master’s degree in Chemical Engineering from the Ecole Polytechnique of Montréal and a Ph.D. in Biochemistry from the University of Quebec at Montréal. Marc was responsible for the formulation and manufacturing development of a variety of novel drug products including solid, liquid and semi-solid formulations and for complex generics including abuse resistant products. Marc is the authors of a number of scientific publications and is named as inventor on patents for novel delivery and excipient technologies. At TALLC Marc is responsible for formulation development, clinical trials batch manufacturing and technology transfer.
Jianmin Duan: Ph.D
Head Pre-Clinical Development
Jianmin worked for 21 years as a senior director drug discovery and development at Boehringer Ingelheim overseeing all translational drug development programs of the company.
Jianmin specializes in in vitro and in vivo drug pharmacology, pharmacokinetics and toxicology, translational studies and IND development.
Bradut Mitrasca: Ph.D
Head of Quality
Bradut brings with him 25 years of experience in pharmaceutical Quality for R&D, API synthesis and clinical trials manufacturing operations. During this period he has overseen successful Health Canada and FDA audits/inspections for products that later reached commercialization. Prior to joining TALLC Bradut was responsible for assembling and managing QC and QA teams for companies including Labopharm Inc. and SGS. Bradut is responsible for Quality and Chemistry activities at TALLC and holds a PhD in physical chemistry.
Enhanced Ocular Delivery of TA-A001
Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001
© TALLC Inc. 2020